Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 05 Mar 2010 Overall survival (OS) and updated results data presented at ASCO 2010 Genitourinary Cancers Symposium.
- 12 May 2009 Actual end date changed from Oct 2008 to Feb 2009 as reported by ClinicalTrials.gov.